| Literature DB >> 27771887 |
Camila Cristina Guimarães Nobre1, Josélio Maria Galvão de Araújo1, Thales Allyrio Araújo de Medeiros Fernandes2,3, Ricardo Ney Oliveira Cobucci1,4, Daniel Carlos Ferreira Lanza5, Vânia Sousa Andrade1, José Veríssimo Fernandes6.
Abstract
Macrophage migration inhibitory factor (MIF) emerged in recent years as an important inflammation mediator, playing a prominent role in the pathogenesis of various types of malignant neoplasm. MIF is a glycoprotein that presents a wide spectrum of biological activities and exerts a complex interaction with various cellular signaling pathways, causing imbalance of homeostasis. Experimental and clinical studies show that high levels of MIF are found in almost all types of human cancers and are implicated in seemingly all stages of development of the tumors. The production of MIF is triggered through an autocrine signal emitted by tumor cells, and stimulates the production of cytokines, chemokines, and growth as well as angiogenic factors that lead to growth of the tumor, increasing its aggressiveness and metastatic potential. MIF is produced by virtually all types of human body cells, in response to stress caused by different factors, leading to pathological conditions such as chronic inflammation and immunomodulation with suppression of immune surveillance and of immune response against tumors, angiogenesis, and carcinogenesis. In this review, we present recent advances on the biological activity of MIF, the signaling pathways with which it is involved and their role in tumorigenesis.Entities:
Keywords: Inflammation; Macrophage migration inhibitory factor; Neoplasms; Tumorigenesis
Mesh:
Substances:
Year: 2016 PMID: 27771887 DOI: 10.1007/s12253-016-0138-6
Source DB: PubMed Journal: Pathol Oncol Res ISSN: 1219-4956 Impact factor: 3.201